These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34074612)

  • 1. Comparison of Upfront Transplantation and Pretransplant Cytoreductive Therapy for Advanced Myelodysplastic Syndrome.
    Wang H; Li Y; Xu Q; Zhou W; Yin C; Wang R; Wang M; Xu Y; Li Y; Yu L
    Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):631-640. PubMed ID: 34074612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
    Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.
    Chen Y; Huang F; Xuan L; Zhang Y; Fan Z; Xu N; Zhao K; Xu J; Liu H; Shi P; Wang Z; Sun J; Zheng W; Dai M; Liu Q
    Int J Cancer; 2021 Sep; 149(5):1109-1120. PubMed ID: 33899230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
    Zhang Y; Liu C; Zhang R; Shi Y; Li X; Yu J; Wan D; Xie X
    Leuk Res; 2023 Jan; 124():106997. PubMed ID: 36502583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis.
    Wang H; Li Y; Zhou W; Wang R; Li Y; Yu L
    Leuk Res; 2021 Nov; 110():106645. PubMed ID: 34217112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors.
    Sun YQ; Xu LP; Liu KY; Zhang XH; Yan CH; Jin J; Huang XJ; Wang Y
    Cancer Commun (Lond); 2021 Apr; 41(4):333-344. PubMed ID: 33566460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].
    Lu CQ; Hou C; Wang P; Zhang LW; Fan Y; Wu DP; Xu Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):247-254. PubMed ID: 35405784
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
    Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
    Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
    Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of the benefit of hypomethylating agents before allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes.
    Liu L; Jia M; Sun L; Tian W; Tang P; Jiang Z
    Clin Exp Med; 2021 Nov; 21(4):537-543. PubMed ID: 33866494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
    Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Damaj G; Mohty M; Robin M; Michallet M; Chevallier P; Beguin Y; Nguyen S; Bories P; Blaise D; Maillard N; Rubio MT; Fegueux N; Cornillon J; Clavert A; Huynh A; Adès L; Thiébaut-Bertrand A; Hermine O; Vigouroux S; Fenaux P; Duhamel A; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1349-55. PubMed ID: 24838178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Yuan XL; Tan YM; Shi JM; Zhao YM; Yu J; Lai XY; Yang LX; Huang H; Luo Y
    Ann Hematol; 2021 Feb; 100(2):517-527. PubMed ID: 33128124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?
    Le Calvez B; Jullien M; Dalle JH; Renard C; Jubert C; Sterin A; Paillard C; Huynh A; Guenounou S; Bruno B; Gandemer V; Buchbinder N; Simon P; Pochon C; Sirvent A; Plantaz D; Kanold J; Béné MC; Rialland F; Grain A;
    Hemasphere; 2024 Jul; 8(7):e120. PubMed ID: 38978638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter retrospective study on the real-world outcomes of autologous vs. allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphoma in China.
    Gu ZY; Dong YJ; Fu XR; Li NN; Liu Y; Wu XX; Wang YN; Li YH; Ren HY; Zhang MZ; Li XF; Wang MH; Wu YM; Liu DH; Wang Z; Hu LD; Huang WR
    Chin Med J (Engl); 2021 Jun; 134(13):1584-1592. PubMed ID: 34133361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.